Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes
Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes
复制标题
DOI：
10.1038/cgt.2011.91
复制
发表时间：
2012-04-01
影响因子：
6.4
通讯作者：
Nakao, A.
中科院分区：
文献类型：
--
作者：
Kanzaki, A.;Kasuya, H.;Nakao, A.
尽管几项研究报告局部给予溶瘤病毒有效靶向恶性肿瘤，但全身给予溶瘤病毒的疗效受到限制。然而，最近，据报道，全身施用吸附在抗原特异性淋巴细胞上的溶瘤性水泡性口炎病毒对恶性肿瘤有效。我们推测静脉注射这种病毒可能在治疗恶性肿瘤方面具有重要的潜力。我们将溶瘤性单纯疱疹病毒-1突变体R3616吸附到从具有获得性抗肿瘤免疫的小鼠收获的淋巴细胞上。我们将吸附的R3616给予腹膜播散的肿瘤并分析这种治疗的功效。施用吸附的R3616的小鼠比施用吸附到非特异性淋巴细胞上的R3616的小鼠或单独施用病毒或肿瘤抗原特异性淋巴细胞的小鼠存活显著更长。在这种情况下，疱疹溶瘤病毒是一个有前途的治疗不仅对原发性病变，而且对多发性转移性病变。这种治疗策略可能成为系统性病毒递送的最有效方法之一。Cancer Gene Therapy（2012）19，292-298; doi：10.1038/cgt.2011.91; 2012年1月27日在线发表
Although several studies have reported that locally administering oncolytic viruses effectively targets malignancies, the efficacy of systemically administered oncolytic viruses is restricted. Recently, however, it was reported that systemic administration of oncolytic vesicular stomatitis virus adsorbed onto antigen-specific lymphocytes was effective against malignancies. We hypothesized that intravenously administering such virus might have significant potential in treatment of the malignant tumors. We adsorbed oncolytic herpes simplex virus-1 mutant R3616 onto lymphocytes harvested from mice with acquired antitumor immunity. We administered adsorbed R3616 to peritoneally disseminated tumors and analyzed the efficacy of this treatment. Mice administered adsorbed R3616 survived significantly longer than mice administered R3616 adsorbed onto non-specific lymphocytes, or mice administered either virus or tumor antigen-specific lymphocytes alone. In this context, herpes oncolytic virus is a promising treatment not only for primary lesions, but also for multiple metastasizing lesions. This treatment strategy may become one of the most effective methods for systemic virus delivery. Cancer Gene Therapy (2012) 19, 292-298; doi:10.1038/cgt.2011.91; published online 27 January 2012